Auristone

Executive Summary

Auristone is a Singapore-based epigenomics company advancing precision oncology through proprietary histone-modification profiling (ChIP-Seq) and RNA-Seq technologies. Its flagship diagnostic, EPI-CALL™, and the Epigenomics-as-a-Service platform, Signomax™, are designed to deliver actionable clinical insights, particularly for Asian cancer cohorts—an underserved population in genomic research. Founded in 2021, the company has raised $5 million and operates at a platform stage, indicating a focus on both diagnostic commercialization and service-based revenue. By leveraging epigenetic biomarkers, Auristone aims to improve treatment selection and drug discovery, addressing the growing demand for personalized medicine in Asia. With a lean team of 50-200, the company is well-positioned to scale through partnerships with pharmaceutical firms and research institutions. The convergence of rising cancer incidence in Asia and increasing adoption of epigenomic tools presents a significant market opportunity for Auristone's differentiated approach.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation data from EPI-CALL™ in Asian cancer cohorts60% success
• Q3 2026Strategic partnership with a major Asian hospital or pharma for Signomax™ platform70% success
• Q2 2026Series A funding round to support commercial expansion50% success